See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Eurovision
Vladimir Putin
Social Media
Education
Baseball
Donald Trump
Trade
European Union
Cricket
Soccer
Senate
Published • loading... • Updated

Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia

Summary by psychiatrictimes.com
Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

2 Articles

All
Left
Center
Right
pharmafile.compharmafile.com

Newron’s programme for treatment-resistant schizophrenia therapy approved - Pharmafile

Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to current antipsychotics in patients with treatment-resistant schizophrenia (TRS). This is a significant milestone Newron’s endeavour to rollout the therapy as a conventional treatment for these patients. The ENIGMA-TRS phase 3 development programme consists of two […] The post Newron’s programme for treat…

Read Full Article
psychiatrictimes.compsychiatrictimes.com

Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

psychiatrictimes.com broke the news in on Monday, May 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal